Journal article
Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
- Abstract:
-
Objective
Report results of patient-reported health-related quality of life (HRQoL) and symptoms from phase III KEYNOTE-006 study of pembrolizumab versus ipilimumab in patients with ipilimumab-naive advanced melanoma.
Patients and Methods
Patients received pembrolizumab 10 mg/kg every 2 (Q2W) or every 3 weeks (Q3W) for up to 2 years, or four cycles of ipilimumab 3 mg/kg Q3W. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnai...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Merck and Co., Inc.
More from this funder
Bibliographic Details
- Publisher:
- Elsevier Publisher's website
- Journal:
- European Journal of Cancer Journal website
- Volume:
- 86
- Pages:
- 115-124
- Publication date:
- 2017-10-01
- Acceptance date:
- 2017-08-28
- DOI:
- EISSN:
-
1879-0852
- ISSN:
-
0959-8049
- Pmid:
-
28987768
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:736892
- UUID:
-
uuid:8e7057b8-5a94-4c1f-ab99-6eee88bcf098
- Local pid:
- pubs:736892
- Source identifiers:
-
736892
- Deposit date:
- 2018-01-25
Terms of use
- Copyright holder:
- Middleton et al
- Copyright date:
- 2017
- Notes:
- © 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record